Jessie Modlin, PharmD, BCOP

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Data shed light on brentuximab vedotin plus nivolumab, bendamustine, or gemcitabine.

Systemic treatment options have historically been limited to traditional chemotherapy agents.